MECOM and myelodysplastic syndrome: Buonamici et al demonstrated Evi1 transduced BM in C57BL6 recipients developed lethal myelodysplastic syndrome (MDS) 8–12 months after bone marrow transplantation (BMT), but none developed AML [10].